Target intelligence / Profile preview

Capsular polysaccharides of 23 Streptococcus pneumoniae serotypes (CPS)

Target
CPS
Molecular classification
Other (bacterial capsular polysaccharide), Virulence factor, Surface antigen
01

Overview

The capsular polysaccharide is a complex carbohydrate structure forming the outermost layer of Streptococcus pneumoniae cells, composed of repeating oligosaccharide units unique to each serotype. These capsules are the primary virulence factors, enabling immune evasion by preventing phagocytosis and defining serotype diversity. Over 100 serotypes exist, but the 23 covered by PPV23 vaccines are responsible for the vast majority of severe pneumococcal infections worldwide. The diversity of capsular polysaccharides presents challenges for vaccine design and epidemiological control, as immune protection is strictly serotype-specific. These capsular polysaccharides do not act as classical receptors or enzymes, but as antigenic targets for immune recognition and vaccine development, making them essential in infectious disease prevention and public health.

Other names
Pneumococcal capsular polysaccharideS. pneumoniae capsule antigenCPSCapsule antigen
02

Mechanism of action

Induction of specific anti-capsular antibodies, promoting opsonophagocytosis and clearance

03

Biological functions

Immune evasion (anti-phagocytosis)Virulence determinantBasis for serotype classification
04

Disease associations

Infection (main role)Invasive pneumococcal disease (IPD), including pneumonia, meningitis, bacteremia, otitis media, and sinusitis
05

Safety considerations

Serotype replacement (non-vaccine serotypes increase in prevalence)Poor immunogenicity in certain populations (infants, immunocompromised)Risk of inadequate coverage due to geographic serotype variationLimited efficacy against non-encapsulated strains
06

Interacting drugs

Pneumococcal vaccines: Pneumococcal polysaccharide vaccine (PPV23)

2 more in the full profile.

07

Biomarkers

Serotype-specific anti-capsular antibody titers (for immunization response and patient selection)Capsule detection by serology (for diagnosis and typing)

Beyond the preview

Go deeper on Capsular polysaccharides of 23 Streptococcus pneumoniae serotypes (CPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Capsular polysaccharides of 23 Streptococcus pneumoniae serotypes (CPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call